Navigation Links
Anthera Pharmaceuticals Reports 2011 Fourth Quarter Financial Results and Provides Clinical Progress Update
Date:2/21/2012

HAYWARD, Calif., Feb. 21, 2012 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH), today announced financial results and business highlights for the quarter ended December 31, 2011.

Financial Results:

Total operating expenses for the fourth quarter ended December 31, 2011 were $28.4 million, as compared to $12.9 million for the same period in 2010. For the 12 months ended December 31, 2011, total operating expenses were $93.1 million, as compared to $35.8 million for the same period in 2010.  Increased operating expenses for the fourth quarter of 2011 and for the full calendar year compared to the same periods in 2010 are primarily due to increased research and development expenses associated with our Phase 2b PEARL-SC clinical study in patients with Systemic Lupus Erythematosus, or lupus, and our VISTA-16 clinical study in patients with Acute Coronary Syndrome, or ACS.

Anthera ended the fourth quarter of 2011 with approximately $67.4 million in cash and cash equivalents and short-term investments.  This is compared to $93.3 million in cash and cash equivalents and short-term investments for the third quarter ended September 30, 2011.

In conjunction with the release of the fourth quarter 2011 financial report, Anthera will host a conference call at 1 p.m. Eastern Time today, February 21, 2012. U.S. and Canadian participants may dial (877) 312-8807; international participants may dial (253) 237-1190.  The Conference ID is 47038854. To access the 24-hour audio replay, U.S. and Canadian participants may dial (855) 859-2056; international participants may dial (404) 537-3406.  The conference ID for the replay is 47038854.  The audio replay will be available until February 28, 2012.

Recent Business Highlights and Upcoming Events:

Clinical

  • In December 2011, the VISTA-16 Data Safety Monitoring Board (
    '/>"/>

  • SOURCE Anthera Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Anthera Announces Completion of Enrollment and Dosing in Phase II Trial of A-002 for the Treatment of Cardiovascular Disease
    2. Anthera Announces Positive Phase II Clinical Results From A-002 Cardiovascular Disease Trial
    3. Antheras A-001 Receives Orphan Drug Status for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
    4. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
    5. Anthera Enters Into Manufacturing Agreements for Varespladib in Preparation for Pivotal Phase III Trials
    6. DSMB Supports Continuation of Anthera Phase II Impacts Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
    7. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
    8. Anthera Completes Special Protocol Assessment With FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval
    9. Following Encouraging Results Anthera to Continue IMPACTS Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
    10. Antheras Varespladib Meets Primary Endpoint in Phase 2 FRANCIS Trial for the Treatment of Acute Coronary Syndrome
    11. Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directors
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/17/2014)... 2014 Los beneficios y ganancias ... nivel de gasto en investigación y desarrollo   ... 30 de septiembre de 2014) ZEISS aumentó sus ingresos ... euros (año anterior: 4.190 millones de euros) a pesar ... (EBIT) crecieron un 14 por ciento, a 360 millones ...
    (Date:12/17/2014)...  Northstar Global Business Services, Inc. (OTCPink:MDIN) today ... made their final decision and has determined to ... effective December 15, 2014, and has resumed accepting ... book entry transfer services. All deposit restrictions have been ... fully "DTC Eligible", and has resumed electronic trading ...
    (Date:12/17/2014)... 2014 , The ... hub of information concerning the biopharmaceutical Group,s national and international ... addition to the recently launched institutional website that is receiving ... enriched by a new chapter in the fascinating story of ... detailed and panoramic hub on the world of clinical research, ...
    Breaking Medicine Technology:ZEISS confirma su posición en un entorno difícil 2Northstar announces that the DTC chill on MDIN has been officially lifted 2Northstar announces that the DTC chill on MDIN has been officially lifted 3Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 2Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 3
    ... 2011 Watson Pharmaceuticals, Inc. (NYSE: WPI ), ... Company intends to release its second quarter 2011 financial results ... the U.S. financial markets.  The Company will also host a ... July 26, 2011 to discuss its financial results and provide ...
    ... BRUSSELS, June 30, 2011 UCB and Harvard University ... ceremony that took place in Boston last night in ... Belgium. (Photo: http://photos.prnewswire.com/prnh/20110630/NY28450 ) ... between industry and academia, with Harvard scientists continuing their ...
    Cached Medicine Technology:Watson to Host Conference Call and Webcast to Discuss Second Quarter 2011 Earnings 2UCB Launches Research Alliance with Harvard University 2UCB Launches Research Alliance with Harvard University 3
    (Date:12/20/2014)... New York, NY (PRWEB) December 20, 2014 ... with the healthcare sector have benefited the Massage ... Given the discretionary characteristics of industry products, the anticipated ... the five-year period has provided consumers with the means ... adults that have received a massage in a given ...
    (Date:12/20/2014)... The print component of Healthy Aging is distributed within ... copies and an estimated readership of 420,000. The digital ... strategy and across a network of top news sites ... the campaign, click here . , The publication ... CTV’s The Social. Lainey Lui, Melissa Grelo, Traci ...
    (Date:12/20/2014)... 2014 The Doctor’s Office Urgent Care of ... part of a decade. They’ve treated over 40,000 patients ... healthcare alternative to the Paramus area. , ... additions to their staff of top-notch board certified physicians: Christine ... These new doctors will work tirelessly to carry ...
    (Date:12/20/2014)... Atore, Inc, (San Francisco, CA CEO: Masashi ... focused portal on December 17th, 2014. , One ... US and Japan. , MERRY BIRTHDAY SITE : ... , MERRY BIRTHDAY MESSAGE is part of 5 future ... Features, Choose from thousands of stock photos to decorate ...
    (Date:12/20/2014)... December 20, 2014 Developers of ... of a new plugin for Final Cut Pro X ... “TranSlice Volume 5 allows users to create hand drawn ... Said Christina Austin, CEO of Pixel Film Studios. “TranSlice ... professionalism while maintaining an easy to use interface.” , ...
    Breaking Medicine News(10 mins):Health News:Massage Services in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Massage Services in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:The ladies of The Social urge Canadian women to put themselves first over the holiday season and into the new year in Mediaplanet’s “Women’s Health” campaign 2Health News:The Doctor's Office Urgent Care Adds 3 New Physicians to Their Growing Medical Team 2Health News:Atore, Inc. Releasing the First Birthday Portal 2Health News:Pixel Film Studios released a new transition entitled TranSlice Volume 5 exclusively for Final Cut Pro X 2
    ... of Innovation in ... Provider, SILVER SPRING, Md. and CAMBRIDGE, Mass., ... for Medical Simulation (CMS) today,announced that they are ... facility,s already cutting edge simulation programs.,B-Line Medical will ...
    ... Inc.,(Nasdaq: CYNO ), a leading developer and ... systems, today announced that the company,will present at ... New York,City. Chief Financial Officer Timothy Baker ... financial results in a presentation,beginning at 1:30 p.m. ...
    ... DEL MAR, Calif., Sept. 10 "Portuguese speaking,Brazil ... surgery," claims Dr.,Barry L. Friedberg. In recognition of ... book, is now scheduled for,a Portuguese translation after ... University Press. Knowledge acquired in this book will,empower ...
    ... marketing campaign celebrates Freedom to Breathe Act, ... of a,new marketing campaign designed to educate and ... statewide smoke-free law that goes into effect,on October ... workplaces smoke-free,including bars, restaurants and private clubs. Called ...
    ... healthy women, breast cancer survivors reported more days of ... in the October 15, 2007 issue of CANCER, a ... who received both chemotherapy and radiotherapy reported the most ... complaint in the general population and, anecdotally, common among ...
    ... be deadly for skiers, mountain climbers, regardless of fitness , ... high altitude pulmonary edema (HAPE) -- a life-threatening buildup of ... -- has been launched at the University of Edinburgh in ... at altitudes as low as 2,500 meters and can affect ...
    Cached Medicine News:Health News:B-Line Medical(TM) and the Center for Medical Simulation Announce Partnership 2Health News:B-Line Medical(TM) and the Center for Medical Simulation Announce Partnership 3Health News:Cynosure to Present at the Maxim Group Growth Conference 2Health News:Cosmetic Surgery & Exotic Brazil 2Health News:Fresh Air Campaign to Showcase Minnesotans' Love of Smoke-Free Air 2Health News:Chemotherapy may be culprit for fatigue in breast cancer survivors 2
    Single-Piece PMMA IOLs for the replacement of the human crystalline lens in the visual correction of aphakia....
    STABIBAG Hydrophilic Acrylic Lens....
    BIGBAG Hydrophilic Acrylic Lens for high myopia....
    One piece multifocal acrylic intraocular lens....
    Medicine Products: